News
A new study found weight loss injections may help reduce the risk of dementia and stroke in people who are obese and have ...
11m
TAG24 on MSNWeight loss jabs linked to lower dementia and stroke riskWeight loss jabs may offer a protective effect against dementia and stroke, according to a new study.People with type 2 diabetes and obesity who are taking the drugs are also less likely to die ...
If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...
Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older ...
Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...
Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared ...
I hear a lot of talk around our small town when someone becomes noticeably thinner. “He sure has lost a lot of weight.” “Did ...
Among patients receiving semaglutide for obesity management, the risk for muscle loss may be higher in older adults and women ...
Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...
Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters, seeking to tap into a market that is ...
Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...
18h
HealthDay on MSNCertain Factors May Predict Weight Fluctuations After GLP-1 Receptor Agonist TreatmentFor adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results